Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505414 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine
A Phase 3 study, sponsored by Grünenthal.
- Terminated
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT00505414 is a Phase 3 study that was terminated before completion, run by Grünenthal. The registered enrollment target is 136 participants.
The verdict
NCT00505414, a Phase 3 study, was terminated before completion, sponsored by Grünenthal.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
Interventions
- DRUG Tapentadol in the Titration Phase
- DRUG Morphine in the Maintenance Phase
- DRUG Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase
- DRUG Tapentadol in the Maintenance Phase
- DRUG Morphine in the Titration Phase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505414
The ClinicalTrials.gov registry entry for NCT00505414 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Grünenthal, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Tapentadol in the Titration Phase is the first listed.
NCT00505414 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505414 about?
NCT00505414 is a clinical study titled "A Study to Evaluate the Effectiveness and Safety of CG5503 (Tapentadol) in the Treatment of Chronic Tumor Related Pain Compared With Placebo and Morphine". The purpose of this study is to determine whether CG5503 (tapentadol) is effective and safe in the treatment of chronic tumor related pain compared to placebo.
What is the current status of trial NCT00505414?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2007-06. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00505414?
The interventions under investigation include: Tapentadol in the Titration Phase (DRUG), Morphine in the Maintenance Phase (DRUG), Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase (DRUG), Tapentadol in the Maintenance Phase (DRUG), Morphine in the Titration Phase (DRUG).
Who is sponsoring clinical trial NCT00505414?
This trial is sponsored by Grünenthal, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.